A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

By Caponigro Francesco   Willemse Pax   Sorio Roberto   Floquet Anne   van Belle Simon   Demol Jan   Tambaro Rosa   Comandini Alessandro   Capriati Angela   Adank Sabine   Wanders Jantien  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 85-89

Springer Publishing Company

Access to resources Recommend Favorite

Overcoming platinum resistance in ovarian carcinoma

By Matsuo Koji   Lin Yvonne G   Roman Lynda D   Sood Anil K  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1339-1354

Informa Healthcare

Access to resources Recommend Favorite

ZD 0473: overcoming resistance to platinum-based chemotherapy

By  

Inpharma, Vol. 1, Iss. 1317, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy

By  

Current Cancer Drug Targets, Vol. 10, Iss. 7, 2010-11 ,pp. : 758-771

Bentham Science Publishers

Access to resources Recommend Favorite

Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 2, 2017-04 ,pp. : 124-133

Bentham Science Publishers

Access to resources Recommend Favorite